Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

14,001 total articles

Palo Alto Networks Tops Q2 Estimates but Cuts Forward Guidance; CEO Says AI Is Not Replacing Cybersecurity

Palo Alto Networks Tops Q2 Estimates but Cuts Forward Guidance; CEO Says AI Is Not Replacing Cybersecurity

Palo Alto Networks reported fiscal second-quarter results that beat analyst expectations on both EPS and revenue, yet the company provided softer-than-expected guidance for the coming quarter and fiscal year. CEO Nikesh Arora pushed back on market concerns that artificial intelligence could render cybersecurity products obsolete, saying customers a…

Athens Stocks Rally as Banking, Construction and Travel Lead Gains

Athens Stocks Rally as Banking, Construction and Travel Lead Gains

Greek equities closed higher on Wednesday, driven by strength in the Banking, Construction and Travel sectors. The Athens General Composite rose 3.30% at the close in Athens. Viohalco and Cenergy were standout performers, each reaching all-time highs, while a small number of stocks in real estate and construction slipped.

RBC Capital Identifies Luxury Sector Winners for 2026: EssilorLuxottica, Hermès, Kering and Pandora Highlighted

RBC Capital Identifies Luxury Sector Winners for 2026: EssilorLuxottica, Hermès, Kering and Pandora Highlighted

RBC Capital Markets has flagged several luxury names as well positioned for 2026, citing recent quarterly results, product innovations and management moves. EssilorLuxottica posted particularly strong Q4 2025 performance aided by its smartglasses partnership and subscription initiatives. Hermès delivered solid margins and reiterated long-term volum…

FDA Agrees to Review Moderna’s Revised Influenza Vaccine Application

FDA Agrees to Review Moderna’s Revised Influenza Vaccine Application

Moderna announced the U.S. Food and Drug Administration will review a revised application for its seasonal influenza vaccine after the agency rejected the company's initial submission a week earlier. The revised filing requests full approval for adults 50-64 and accelerated approval for those 65 and older, and includes a commitment to a post-market…